Reversible sideroblastic anemia associated with the tetracycline analogue COL-3

Michelle A. Rudek, McDonald Horne, William D. Figg, William Dahut, Valerie Dyer, James M. Pluda, Eddie Reed

Research output: Contribution to journalArticlepeer-review

Abstract

Eight of 35 patients with cancer receiving COL-3, a tetracycline derivative with antiangiogenic properties, developed anemia while on treatment. All of these patients were enrolled on an approved Phase I clinical trial at the National Cancer Institute. Three of these patients had bone marrow examinations that revealed ringed sideroblasts. This paper describes these cases.

Original languageEnglish (US)
Pages (from-to)51-53
Number of pages3
JournalAmerican journal of hematology
Volume67
Issue number1
DOIs
StatePublished - 2001
Externally publishedYes

Keywords

  • Anemia
  • COL-3
  • Cancer
  • Phase I
  • Sideroblast
  • Tetracycline

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Reversible sideroblastic anemia associated with the tetracycline analogue COL-3'. Together they form a unique fingerprint.

Cite this